: A diabetes drug has been authorised to help obese and overweight adults with weight management and loss, according to the Medicines and Healthcare products Regulatory Agency .
The weight loss jab, also known as Mounjaro, was given the green light for NHS use in September by Nice as an option for patients with type 2 diabetes who do not have the condition under control. The MHRA’s authorisation is based on the results of two clinical trials, which showed that patients who were treated with Tirzepatide “had a significant weight loss over time compared to patients who took a placebo.”
It also listed potential side effects of the medicine, including nausea, diarrhoea, vomiting - which usually goes away over time - and constipation.Julian Beach, MHRA interim executive director, healthcare quality and access, said: “We have prioritised rapid assessment of this new indication for Mounjaro, given the public health importance of access to new medicines to help tackle obesity.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: fmtoday - 🏆 5. / 72 Read more »
Source: fmtoday - 🏆 5. / 72 Read more »
Source: fmtoday - 🏆 5. / 72 Read more »
Source: theSundaily - 🏆 25. / 51 Read more »
Source: fmtoday - 🏆 5. / 72 Read more »
Source: fmtoday - 🏆 5. / 72 Read more »